VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Lantheus Holdings Executive Compensation (FY25)

LNTH · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Mary Anne Heino
Median of the other named officers
$5,315,120
6 officers, excluding the chief executive
Latest say-on-pay support
=
April 30, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Lantheus Holdings brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): May 1, 2026
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Lantheus Holdings brief$500Get the executive brief
Velarion Intel, one year, every company
427 figures on this page: 421 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Mary Anne Heino: $787,596 → $2,173,930 (176.0% higher)
CEO pay ratio: 66:1 → 79:1 (19.7% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Lantheus Holdings' chief executive and what were they paid?
Mary Anne Heino was paid $2,173,930 in total compensation as Executive Chairperson and Chief Executive Officer for fiscal 2025. Compared with the $787,596 reported for fiscal 2024, Heino's total was 176.0% higher.
What was Lantheus Holdings' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 96.5% support at the meeting held April 30, 2026.
Which companies are in Lantheus Holdings' peer group?
The disclosed peer group names Acadia Pharmaceuticals, Alkermes, Apellis Pharmaceuticals, Azenta and Bio-Rad Laboratories, among others.
What is Lantheus Holdings' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 79:1, against median employee compensation of $194,254.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mary Anne Heino
Former Chief Executive Officer
◇—◇◇◇—◇◇
Robert Marshall Jr.
Chief Financial Officer and Treasurer
◇◇◇◇◇—◇◇
Paul Blanchfield
President
◇—◇◇◇—◇◇
Etienne Montagut
Former Chief Business Officer
◇◇◇◇◇—◇◇
Daniel Niedzwiecki
Chief Administrative Officer, General Counsel and Corporate Secretary
◇◇◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mary Anne Heino
Former Chief Executive Officer
◇—◇◇◇—◇◇
Paul Blanchfield
President
◇—◇◇◇—◇◇
Robert Marshall Jr.
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Daniel Niedzwiecki
Chief Administrative Officer, General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
Jean-Claude Provost
Chief Science Officer
◇—◇◇◇——◇
Etienne Montagut
Former Chief Business Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Markison
Chief Executive Officer
◇—◇—◇—◇◇
Robert Marshall Jr.
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Paul Blanchfield
President
◇—◇◇◇—◇◇
Daniel Niedzwiecki
Chief Administrative Officer, General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
Etienne Montagut
Former Chief Business Officer
Departed during or after this year
◇—◇◇——◇◇
Jean-Claude Provost
Chief Science Officer
◇—◇◇◇—◇◇
Amanda Morgan
Chief Commercial Officer
◇—◇◇◇—◇◇
Mary Anne Heino
Former Chief Executive Officer
Departed during or after this year
◇—————◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ludger Dinkelborg
Head of Research and Development
◇—◇◇◇—◇◇
Brian Markison
Former Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Paul Blanchfield
Former President
Departed during or after this year
◇—◇◇——◇◇
Robert Marshall Jr.
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Daniel Niedzwiecki
Chief Administrative Officer, General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
Amanda Morgan
Chief Commercial Officer
◇—◇◇◇—◇◇
Mary Anne Heino
Executive Chairperson and Chief Executive Officer
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Amanda M. MorganOPTION◇——◇—◇◇
Amanda M. MorganRSU◇——◇——◇
Amanda M. MorganPSU◇◇◇—◇—◇
Brian A. MarkisonPSU◇◇◇—◇—◇
Brian A. MarkisonRSU◇——◇——◇
Brian A. MarkisonOPTION◇——◇—◇◇
Daniel M. NiedzwieckiRSU◇——◇——◇
Daniel M. NiedzwieckiPSU◇◇◇—◇—◇
Daniel M. NiedzwieckiOPTION◇——◇—◇◇
Ludger DinkelborgOPTION◇——◇—◇◇
Ludger DinkelborgRSU◇——◇——◇
Mary Anne HeinoOPTION◇——◇—◇◇
Mary Anne HeinoRSU◇——◇——◇
Paul M. BlanchfieldRSU◇——◇——◇
Paul M. BlanchfieldOPTION◇——◇—◇◇
Paul M. BlanchfieldPSU◇◇◇—◇—◇
Robert J. Marshall JrRSU◇——◇——◇
Robert J. Marshall JrPSU◇◇◇—◇—◇
Robert J. Marshall JrOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Brian MarkisonPSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇3/5/2035
RSU◇◇——
Mary HeinoPSU◇◇——
Option◇—◇11/17/2035
Option◇—◇3/2/2033
RSU◇◇——
RSU◇◇——
Option◇—◇5/14/2035
RSU◇◇——
Robert MarshallPSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇3/1/2034
Option◇—◇3/5/2035
RSU◇◇——
RSU◇◇——
Option◇—◇3/2/2033
RSU◇◇——
RSU◇◇——
Daniel NiedzwieckiPSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇3/5/2035
Option◇—◇3/1/2034
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇3/2/2033
RSU◇◇——
Option◇—◇4/17/2033
RSU◇◇——
Dr. DinkelborgOption◇—◇8/15/2035
RSU◇◇——
Amanda MorganPSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇3/5/2035
Option◇—◇3/1/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Amanda Morgan
Chief Commercial Officer · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Brian Markison
Former Chief Executive Officer · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Daniel Niedzwiecki
Chief Administrative Officer, General Counsel and Corporate Secretary · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Ludger Dinkelborg
Head of Research and Development · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Mary Anne Heino
Executive Chairperson and Chief Executive Officer · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Paul Blanchfield
Former President · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Robert Marshall Jr.
Chief Financial Officer · Severance agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dr. Phuong Khanh (P.K.) Morrow
◇◇◇———◇
Julie McHugh
Lead independent director
◇◇◇———◇
Gary J. Pruden
◇◇◇———◇
Samuel Leno
◇◇◇———◇
Dr. James H. Thrall
◇◇◇———◇
Minnie Baylor-Henry
◇◇◇———◇
Heinz Mäusli
◇◇◇———◇
Julie Eastland
◇◇◇———◇
Dr. Gérard Ber
◇◇◇———◇
Brian A. Markison
——————◇
Mary Anne Heino served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Acadia Pharmaceuticals ACAD
  • Alkermes ALKS
  • Apellis Pharmaceuticals APLS
  • Azenta AZTA
  • Bio-Rad Laboratories BIO
  • Bio-Techne TECH
  • BioMarin Pharmaceutical BMRN
  • Bruker BRKR
  • Exact Sciences EXAS
  • Exelixis EXEL
  • Haemonetics HAE
  • Halozyme Therapeutics HALO
  • Ionis Pharmaceuticals IONS
  • Neurocrine Biosciences NBIX
  • Repligen RGEN
  • Sarepta Therapeutics SRPT
  • United Therapeutics UTHR
  • Waters WAT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 30, 2026=◇◇◇
2024May 1, 2025=◇◇◇
2023April 25, 2024=◇◇◇
2022April 27, 2023=◇◇◇
2021April 28, 2022=◇◇◇
2020April 28, 2021=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Mary Anne Heino (Executive Chairperson and Chief Executive Officer), FY2025 total compensation $2,173,930 (base salary $100,000) [exec_comp, SEC accession 0001193125-26-117649, filed 2026-03-20]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Lantheus Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Lantheus Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Lantheus Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Lantheus Holdings' disclosed peer group is defensible, who names Lantheus Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
427 figures on this page: 421 cited to the filing that reported them, 6 calculated from figures it prints.
421 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001193125-26-201556
  2. 0001193125-26-117649
    DIRECTOR COMPENSATION · Director Compensation · Grants of Plan-Based Awards for Fiscal 2025 · Our Named Executive Officers · and 3 more sections
  3. 0001193125-25-112812
  4. 0001193125-25-060360
    Summary Compensation Table for Fiscal Years 2024, 2023 and 2022
  5. 0001193125-24-122683
  6. 0001193125-24-068590
    Summary Compensation Table for Fiscal Years 2023, 2022 and 2021
  7. 0001193125-23-130535
  8. 0001193125-22-136860
  9. 0001193125-21-140557
  10. 0001628280-19-001574
    Employment Agreement
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Lantheus Holdings executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/LNTH (accessed 2026).
Short form: data: Velarion

The Lantheus Holdings brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Lantheus Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Lantheus Holdings discloses

The companies named in LNTH's own disclosed peer group.

Acadia PharmaceuticalsAlkermesApellis PharmaceuticalsAzentaBio-Rad LaboratoriesBio-TechneBioMarin PharmaceuticalBrukerExact SciencesExelixisHaemoneticsHalozyme TherapeuticsIonis PharmaceuticalsNeurocrine BiosciencesRepligenSarepta TherapeuticsUnited TherapeuticsWaters

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy